You are here

efruxifermin

Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst

Fierce Biotech

Mon, 01/27/25 - 11:27 am

Akero Therapeutics

clinical trials

Akero, bruised from earlier failure, soars as liver scarring improves in longer MASH trial

Fierce Biotech

Mon, 03/4/24 - 11:21 am

Akero Therapeutics

Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash

Fierce Biotech

Tue, 10/10/23 - 10:10 am

Akero Therapeutics

clinical trials

Akero’s NASH drug combined with Ozempic cut liver fat in small study

Stat

Mon, 06/5/23 - 10:10 am

Akero Therapeutics

Akero hits endpoints in midphase NASH trial, linking candidate to improvements in fibrosis

Fierce Biotech

Tue, 09/13/22 - 10:40 am

Akero Therapeuticsw

clinical trials

Analysts hail Akero's midphase NASH data as best in class

Fierce Biotech

Thu, 07/2/20 - 11:10 am

Akero Therapeutics

clinical trials